In recent years, the pharmaceutical business has faced unprecedented challenges. The last three years have seen a 24% increase in the average cost of medications in the US due to safety concerns, issues with specific prescriptions, and competition from both non-generic and generic treatments. This resulted in a 4% drop in prescription expenses for those with private insurance between 2010 and 2013.Developing nations like China, India, and Brazil have comparable difficulties. Creating a line of vaccines with therapeutic qualities is one such intervention.In order to treat bacterial illnesses and maintain population and individual health over the long term, antibiotics are required. However, bacterial diseases resistant to antibiotics pose a threat to international health.